Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Taisho discloses promoters of NGF production

Feb. 27, 1997

Pfizer licenses potential stroke therapy

Feb. 26, 1997

Melatonin agonists from Takeda

Feb. 26, 1997

5-HT2C antagonists from Roche

Feb. 26, 1997

MS&D discloses tachykinin antagonists

Feb. 26, 1997

Watson's analgesic receives FDA approval

Feb. 25, 1997

Novo Nordisk prepares compounds with high affinity for 5-HT2C receptors

Feb. 25, 1997

Acorda and Elan to collaborate on spinal cord injury treatment

Feb. 24, 1997

Licenses offered for vasospasm therapy

Feb. 24, 1997

NIH seeks licensees for antispasmodic immunotoxin

Feb. 24, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...